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Abstract
Background: Plasmodium falciparum Apical Membrane Antigen 1 (PfAMAI) is a candidate vaccine antigen expressed by 
merozoites and sporozoites. It plays a key role in red blood cell and hepatocyte invasion that can be blocked by antibodies.
Methodology/Principal Findings: We assessed the safety and immunogenicity of recombinant PfAMAI in a dose- 
escalating, phase la trial. PfAMAI FVO strain, produced in Pichia pastoris, was reconstituted at 10 mg and 50 mg doses with 
three different adjuvants, Alhydrogel™, Montanide ISA720 and AS02 Adjuvant System. Six randomised groups of healthy 
male volunteers, 8-10 volunteers each, were scheduled to receive three immunisations at 4-week intervals. Safety and 
immunogenicity data were collected over one year. Transient pain was the predominant injection site reaction (80-100%). 
Induration occurred in the Montanide 50 mg group, resulting in a sterile abscess in two volunteers. Systemic adverse events 
occurred mainly in the AS02 groups lasting for 1-2 days. Erythema was observed in 22% of Montanide and 59% of AS02 
group volunteers. After the second dose, six volunteers in the AS02 group and one in the Montanide group who reported 
grade 3 erythema (>50 mm) were withdrawn as they met the stopping criteria. All adverse events resolved. There were no 
vaccine-related serious adverse events. Humoral responses were highest in the AS02 groups. Antibodies showed activity in 
an in vitro growth inhibition assay up to 80%. Upon stimulation with the vaccine, peripheral mononuclear cells from all 
groups proliferated and secreted IFNy and IL-5 cytokines.
Conclusions/Significance: All formulations showed distinct reactogenicity profiles. All formulations with PfAMA1 were 
immunogenic and induced functional antibodies.
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Introduction
In  sub-Saharan  Africa the b u rden  o f death  an d  disease from 
Plasmodium falciparum m alaria  is particularly  severe. T o  date, there 
are no approved vaccines to help reduce this burden , a lthough a 
num ber o f candidate vaccines have been  pu t forward. T he 
m ajority o f the candidates target the pre-erythrocytic circum spor- 
ozoite p rotein  (CSP) an d  the m erozoite proteins M erozoite Surface
Protein  1 (MSP1) an d  Apical M em brane Antigen 1 (AMA1)[1]. 
T h e  R T S ,S  candidate vaccine has shown efficacy in infants and  
children [2,3] an d  a phase III clinical trial is p lanned. T h e  MSP1 
and  AMA1 candidate vaccines are in early stage clinical 
developm ent and  efficacy trials will provide inform ation to 
determ ine w hether these antigens are suitable targets, and  w hether 
they can  be deployed singly o r as com ponents of a  m ultivalent 
m alaria  vaccine.
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Following an  infected m osquito bite, P. falciparum sporozoites 
m igrate to hepatocytes, each developing over a  period  o f a  week to 
release several thousand  m erozoites. These initiate cyclical asexual 
b lood stage developm ent, producing  m erozoites th a t invade 
erythrocytes. AMA1 is an  integral m em brane pro tein  o f 
m erozoites an d  sporozoites an d  has a  central role in parasite 
invasion o f erythrocytes an d  potentially hepatocytes th a t can be 
inhibited by  anti-A M A l antibody [4-6]. In  m erozoites, AMA1 is 
synthesised as an  83 kD a m olecule originally localised to the 
m icronem e. A round  the tim e of m erozoite release and  the 
subsequent rap id  erythrocyte invasion, the pro tein  is N-term inally 
cleaved to a  66 kD a form. This translocates to the m erozoite 
surface and  undergoes secondary proteolytic processing, shedding 
soluble fragm ents (44 o r 48 kDa) [7].
Im m unisation  w ith AMA1 can provide protection  against 
infection in experim ental anim al m odels, an d  can  induce 
antibodies th a t show functionality in in vitro grow th inhibition 
assays (GIA). How ever, AM A1 is polym orphic and  im m une 
responses have varying degrees o f strain specificity an d  growth 
inhibition [8].
Previous Phase I trials have shown th a t grow th inhibitory 
antibodies can be induced by im m unisation w ith PfAMA1 [9,10], 
b u t im m unogenicity varied depending on the vaccine form ulation. 
In  particular, the choice o f adjuvant has a  m ajor effect on  the 
safety, stability, im m unogenicity and, presum ably, eventual 
efficacy o f a  vaccine [11]. A djuvants can be tools th a t channel 
the im m une reponse to generate high levels o f the desired type of 
long-lived im m unity. AlhydrogelTM, an  alum inum  salt, is the m ost 
widely used adjuvant in licensed hum an  vaccines and  is therefore 
used as a  standard  to com pare o ther adjuvants. U nfortunately, in 
com bination with m alaria  antigens, it has generally induced poor 
reponses [12-15]. M ontanide ISA 720, a  squalene based water-in- 
oil adjuvant form ulation has shown prom ising results in previous 
m alaria  vaccine trials [16-19], possibly due to the slow-release 
capacity o f the inert w ater-in-oil em ulsion and  im m une stim ulating 
effects o f its com ponents [20]. AS02, a  p roprietary  A djuvant 
System from  G laxoSm ithK line Biologicals based on an  oil-in- 
w ater form ulation, contains 50 mg each o f the im m unostim ulants 
m onophosphoryl lipid A (MPL) and  Q uillaja saponaria 21 (QS21) 
[21]. It has been  used to adjuvant the R T S ,S  m alaria  candidate 
vaccine th a t targets CSP. T o  date, this candidate is the only 
m alaria  vaccine th a t has induced protection  in adults, children and  
infants in na tu ra l field trials [22-25]. W hen  com bined with 
Alhj>drogelTM, R T S ,S  did no t convey protection  in a  com bined 
phase I / I I a  trial [26]. AS02 is capable o f  eliciting high antibody 
titers along w ith strong cell-m ediated im m unity [27], bo th  o f 
w hich are believed to contribute to the efficacy of the R T S ,S  
candidate vaccine [28].
Because of their central role in vaccine form ulation, the 
developm ent o f adjuvants and  delivery systems have becom e 
increasingly im portant. T his study aims a t com paring  the safety 
and  im m unogenicity o f PfAMA1 in two dosages form ulated with 
three  different adjuvants in a  phase Ia  trial.
Materials and Methods
Vaccine preparation
Clinical grade PfA M A1-FVO [25-545] was developed[29] and  
produced[30] as previously reported . In  brief, F V O  strain 
PfAMA1 was codon adap ted  to expression in the m ethylotrophic 
yeast Pichia pastoris. Glycosylation sites w ere conservatively 
m utated , and  the ectodom ain  com prising am ino acids 25-545 
was expressed. PfA M A 1-FV O [25-545] p repara tion  was m anufac­
tu red  and  lyophilised according to curren t good m anufacturing
practice in m ultidose vials containing either 120 mg (44 mg E D TA , 
180 mg sucrose and  120 mg N a H C O 3, lo t B) o r 62.5 mg (23 mg 
E D T A , 25 m g saccharose, 226 mg K 2H P O 4 and  187 mg 
N a H 2P O 4, lo t C) o f  AM A1 th a t were stored betw een — 18°C 
and  — 30°C and  betw een +2 an d  +8°C respectively. Q uality  
control and  stability da ta  are described by Faber e t al. [31]. 
R econstitution and  m ixing o f vaccine with adjuvant was 
perform ed under sterile conditions under responsibility o f  the 
hospital pharm acist.
PfAMA1 vaccine a t 50 mg (high dose) and  10 mg (low dose) 
PfAMA1 per injection (0.5 ml) was form ulated with three  different 
adjuvants and, after p reparation , was kept a t a  constant tem perature 
o f +4°C for a  m axim um  o f six hours until injection. For the 
Alhydrogel™ form ulation, 1.2 ml alum inum  hydroxide suspension at 
2 m g /m l (Statens Serum  Institut (SSI), Copenhagen, Denm ark) was 
added  to the 120 mg PfAMA1 vial (lot B) to obtain  a  high dose 
(50 mg in 0.5 ml) an d  6 ml was added  to obtain  a  low dose (10 mg in 
0.5 ml) form ulation. T h e  resulting am oun t o f alum inum  in each 
vaccine was 0.5 mg. Stability studies confirm ed adsorbtion of 
99.9%  of the antigen to the alum inum . M ontanide form ulations 
were p repared  by  dissolving the contents o f  the 120 mg PfAMA1 vial 
(lot B) in  sterile phosphate buffered saline (145 m M  N aC l, 5 m M  
Phosphate, p H  7.4), 0.32 ml for the high dose an d  1.6 ml for the 
low dose form ulation. M ontanide ISA 720 (SEPPIC, Paris, France) 
was subsequently added, 0.88 ml for the high dose to obtain 1.2 ml 
o f form ulation (50 mg pfAMA1 in 0.5 ml) and  4.4 ml for the low 
dose to obtain 6 ml o f form ulation o f which five 10 mg -FJAMA1 in 
0.5 ml doses could be  p repared . T h e  suspension was p repared  by 
m anually pushing th rough  a 22 gauge syringe coupling piece 
(3038068 O m nilabo International, Breda, T h e  Netherlands) at 
+20C° for twenty up and  dow n strokes.
T h e  suspension was confirm ed to be  hom ogeneous an d  reached 
a m edian  droplet size o f approxim ately 1.5 mm (SD 0.17 mm) by 
particle size m easurem ents w ith the M alvern M astersizer S by 
SEPPIC .
For the AS02 form ulation, the contents o f one vial o f  lyophilized 
PJAMA1 contain ing  62.5 mg of antigen (lot C) was m ixed by gentle 
shaking w ith AS02 (approxim ately 0.6 ml) [32]. A 0.5 ml dose 
contained approxim ately 50 mg AMA-1 in  500 ml AS02 (high 
dose). For low  dose preparations (10 mg) five times m ore AS02 
adjuvant was added  to the 62.5 mg vial o f AM A1, from  w hich five
0.5 ml low vaccine doses could be obtained.
Study design
T h e  protocol for this trial an d  supporting C O N S O R T  checklist 
are available as supporting inform ation; see Checklist S1 and  
Protocol S1 w ith A m endm ents S2, S3, S4, S5, S6 and  S7. T he 
study was designed as a  dose-escalating phase Ia  trial to assess the 
safety and  im m unogenicity o f two dosages o f  PfAMA1 with three 
different adjuvants. V olunteers w ere thus random ised into six 
different groups, each  o f w hich was aim ed to constitute o f a  lim ited 
num ber o f 10 volunteers for safety reasons. R andom isation  was 
perform ed by an  external statistician in six blocks th rough  a 
com puter program . Block random ization  were used to ensure 
equal distribution o f adjuvants am ong the im m unisation groups. 
T h ere  was no stratification for sex a n d /o r  age. T h e  random ization  
list was provided to the pharm acy  departm ents. T h e  clinical 
investigators allocated the nex t available num ber on  entry  into the 
trial. T h e  code was revealed to the researchers once recruitm ent, 
da ta  collection, and  laboratory  analyses were com plete. T he 
im m unisations were thus perform ed blind, so neither volunteers, 
nor investigator o r labora to ry  personnel were aw are o f the 
adjuvant allocation. Because o f the dose-escalating design, the trial 
could no t be blinded for dose.
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For logistical reasons, the AS02 adjuvanted  groups were 
im m unised nine m onths after the AlhydrogelTM an d  M ontanide 
groups, breaking the blind for this trial arm . A subsequent bias 
canno t form ally be excluded b u t seems unlikely, since all trial 
procedures were identical. All im m unisations were perform ed 
intram uscularly  in the deltoid region o f alternate arm s a t 0, 4 and  
8 weeks.
Participants
W e aim ed to recruit 60 healthy, m alaria  naive m ale volunteers, 
aged betw een 18 to 45 years th rough  advertisem ents a t the 
R ad b o u d  U niversity N ijm egen M edical C entre. Potential volun­
teers provided a m edical history and  a  physical exam ination was 
conducted  with routine labora tory  tests consisting of full blood 
count, serum  biochem istries and  serologic assays for hum an  
im m unodeficiency virus, hepatitis C an d  B virus. V olunteers were 
excluded from  participation  if  they h ad  any symptoms, signs or 
laboratory  values suggestive o f  systemic illness, including renal, 
hepatic, cardiovascular, pulm onary , skin, im m unodeficiency, 
psychiatric and  o ther conditions, w hich could interfere w ith the 
in terpreta tion  o f the study results or com prom ise the health  o f the 
volunteers, o r received chronic m edication, h ad  a  history o f drug  
or alcohol abuse interfering with social function one year p rio r to 
enrolm ent, or a  know n hypersensitivity to any of the vaccine 
com ponents. A dditional reasons for exclusion were a history of 
m alaria  o r residence in m alaria  endem ic areas w ithin the past six 
m onths, previous participation  in a  m alaria  vaccine trial or 
receiving vaccines o ther th an  the study vaccines. Furtherm ore, 
volunteers were not enrolled in any o ther clinical trial, an d  agreed 
to rem ain  available to be closely m onitored. All volunteers 
provided w ritten  inform ed consent. T h e  study was approved by 
the Institutional Review  B oard (C M O  Regio A rnhem -N ijm egen, 
2005/015). T h e  study was conducted  in accordance w ith the 
D eclaration  o f Helsinki principles for the conduct o f  clinical trials 
and  the In ternational C om m ittee o f H arm onization  G ood Clinical 
Practice Guidelines [33] an d  registered a t www.clinicaltrials.gov 
(NCT00730782).
Assessment of safety
V olunteers w ere observed for 30 m inutes and  evaluated on days
1, 3, 7 and  14 after every im m unisation. A t each visit, local and  
systemic reactogenicity was assessed by a physician and  findings 
recorded and  scored as follows: grade 1, m ild reaction (easily 
tolerated), grade 2, m oderate reaction (interferes w ith norm al 
activity), o r grade 3, severe reaction  (prevents norm al activity). 
Redness, swelling an d  induration  (according to B righton collab­
oration  definitions, w w w .brightoncollaboration.org) w ere m ea­
sured w ith a  ruler, and  categorised according to the longest 
d iam eter as grade 1: # 2 0  m m , grade 2: > 2 0  and  # 5 0  m m , grade 
3: > 5 0  m m . T em pera tu re  was m easured w ith an  oral therm om ­
eter; fever intensity was defined as grade 1 (37.5°C to 38°C), grade
2 (> 38°C  to 39°C) o r grade 3 (>39°C ). T h e  following adverse 
events were solicited and  recorded routinely during  the 14 days 
after im m unisation: injection site pain, redness and  swelling, 
systemic fatigue, fever, headache, malaise, m yalgia, jo in t pain, 
gastrointestinal sym ptoms and  contralateral local reactions.
Blood samples
Safety was also determ ined by  serial laboratory  evaluations o f 
clinical chem istry an d  haem atology on blood samples collected 7 
and  28 days after im m unisation. For evaluation of im m unogenic- 
ity, blood was collected in V acutainer C P T  tubes (Becton and  
Dickinson) and  processed w ithin two hours after collection on 
im m unisation days, one m onth  after each im m unisation and  on
Days 140 and  365. Plasm a was collected after centrifugation 
(2000 g 15') a liquoted an d  stored a t —20°C for antibody analysis 
(ELISA, Im m uno Fluorescence Assay (IFA) and  G row th Inhibition 
Assay (GIA)). Peripheral blood m ononuclear cells (PBMC) were 
collected, w ashed in PBS (800 g, 10 min) and  im m ediately used 
for assays (lymphocyte stim ulation assay and  ELISPO T).
Measurement of anti-AMA1 antibodies by ELISA and IFA
Antibody to PfAMA1 was m easured using a  standardized ELISA 
protocol. All procedures used Phosphate buffered saline (PBS) and 
for washing steps 0.05% T w een 20 (Sigma-Aldrich). Briefly, wells in 
96-well polystyrene plates (NU NC M axisorp, Sanbio), were coated 
overnight (100 ml, 0.5 m g/m l PfAMA1, 4°C), washed (3x), blocked 
(60 m in, 3% BSA (Sigma-Aldrich)) an d  w ashed (3 x) before addition 
o f 100 mL from  duplicate dilution series (diluted in PBS-Tween 
BSA, one hour, +37°C). After washing (3x) goat anti-hum an IgG  
alkaline phosphate (Perbio Science) diluted 1:1250 in 0.5% BSA, 
0.05%  T w een was added, (one hour, +37°C). Plates were washed 
and  100 ml o f 1 m g /m l para-nitro-phenyl-phosphatase (Fluka, 
Sigma-Aldrich) substrate was added (30 m inutes, room  tem pera­
ture). A hu m an  plasm a pool from  a  m alaria  endem ic area  was used 
as reference positive control, whereas a  plasm a pool from  eight 
healthy m alaria-naive D utch  volunteers was used as a  negative 
control. O ptical density was m easured a t 405 nm . V ariation 
betw een duplicates was set to a  m axim um  of 15%. M easurem ents 
with a  greater variation were repeated. T h e  standard  curve of 
hu m an  plasm a pool from a m alaria  endem ic area, defined to 
contain 400 A rbitrary Units, was fitted to a  four-param eter 
hyperbolic function, using the AD A M SEL program  (E. R em arque, 
unpublished work). U sing this standard  curve, optical density from 
samples w ere converted to A rbitrary Units (AU). Test samples that 
d id not fall w ithin the linear pa rt o f the optical density range o f the 
standard  were tested at alternate dilutions.
IFA was perform ed on cultured P. falciparum parasitized red blood 
cells. T en  well black slides (30-966-A black, Nutacon, T he N ether­
lands) were coated with a  washed parasite suspension of 3 x 1 0 6 
parasites/m l, air dried and kept a t —80°C until used. FC R 3 parasites, 
expressing an AMA1 protein with one am ino-acid difference from 
the FV O  parasites, and N F54 strain parasites, with 26 amino-acid 
difference in AMA1 protein were used to prepare slides.
Based on antibody titers by ELISA on day 84, a  representative 
sample o f  fifteen sera was selected for IFA, containing a t least two 
samples from  each adjuvant group and  at least three  samples with 
low, interm ediate o r h igh ELISA titers. Before use slides were 
b rought to room  tem perature  in an  evacuated exicator. Plasm a 
was diluted in PBS (1:40, 1:80, 1:160, 1:320, 1:640) and  a final 
volum e o f 20 mL was added  to the wells and  incubated  for 
0.5 hour, at room  tem perature. As for the ELISA protocol, the 
m alaria-naive blood bank donor plasm a pool was used as a 
negative control and  h u m an  m alaria  endem ic plasm a was used as 
a  positive control. After washing (2 x  in PBS) and  air drying, slide 
samples w ere incubated  w ith rabb it an ti-hum an Im m unoglobin 
F IT C  (F0200, D A K O , Denm ark) in 0.05%  w.v Evans Blue (3169, 
Merck), PBS for 30 m inutes at room  tem perature. Slides were 
w ashed twice and  incubated  for 15 m inutes with D A PI (4'-6- 
D iam indino-2-phenylindole, 24653, M erck, D arm stadt, G er­
many), 5 m g/m l in PBS. After washing (2 x  in PBS) slides were 
m ounted  with V ectashield M ounting  M edium  (H-1000, Brunsch- 
wig, Am sterdam ), covered w ith a  deck-slide and  read  im m ediately 
by two independent b linded exam iners. Exam iners identified the 
highest dilution still showing a  staining p a tte rn  above the 
background of pre-im m unisation samples. Differences betw een 
exam iners were never greater th an  one dilution and  the m ean  of 
b o th  dilutions was taken.
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ELISPOT for IFNy and IL-5
E L IS P O T  was perform ed according to m anufacturer’s instruc­
tions (Becton and  D ickinson Elispot Set H u m an  IFN y or IL-5). In 
sum m ary, plates provided in the set were coated  w ith either IFN y 
or IL-5 capture  antibody (5 m g/m l, overnight, 4°C). After blocking 
with com plete m edium  solution (RPM I 1640 (Invitrogen) 
contain ing 10% Fetal Bovine Serum  (FBS Invitrogen, Breda, 
T h e  Netherlands), 1% G lutam ax (Invitrogen), 1% Penicillin­
Streptom ycin (G IB C O -B R L, Invitrogen), 1% M EM ) 100 ml o f 105 
PBM C suspension and  100 ml o f PfAMA1 containing either 
60 mg, 12 mg or 2.4 mg was added  pe r well. Positive controls were 
stim ulated with T etanus T oxoid  10 m g/m l (RIVM , Bilthoven, 
T h e  N etherlands) an d  phytohaem agglutinin 5 m g/m l (PHA-L 
Sigma-Aldrich) end concentration . Negative controls w ere incu­
ba ted  with com plete m edium  solution (mean S F C /1 0 5 cells 
3 1 6 1 7  for IFN y and  9 6 7  for IL-5). After incubation  (40 hours, 
37°C in hum idified 5% C O 2), biotinylated anti h um an  IFN y and  
IL-5 (0.25 m g/m l an d  2 mg/m l, respectively), contain ing 10% FBS 
was added  (two hours a t room  tem perature). S treptavid in-H R P 
was used as an  enzym e conjugate. D etection was perform ed with 
the Becton an d  Dickinson AEC Substrate R eagent Set, according 
to m anufacturer’s instruction. Spot-form ing cell num bers were 
counted  by E L IS P O T  reader (4 M icrotiter Plate R eader, 
AELVIS, Sanquin, Am sterdam ) an d  analysed by the E L IS P O T  
Analysis Software Version 4.0 (Sanquin, Am sterdam ). All 
m easurem ents w ere perform ed in triplo. V ariation  betw een 
triplicates was set to a  m axim um  of 20% .
Lymphocyte Stimulation Assay
Lym phocyte stimulation assays were perform ed as described 
previously [34]. Peripheral blood m ononuclear cell suspension 
(PBMC) was diluted to 1 x 1 0 6 PBM C per ml in D ulbecco’s M E M  
(DM EM ) with G lutam ax-I, 2 m M  pyruvate an d  h igh Glucose 
(G IB C O  BRL, Invitrogen) supplem ented w ith 10 m M  H E PE S 
buffer (G IB C O  BRL, Invitrogen), 100 IU /m L  Penicillin-Strepto­
m ycin (G IB C O  BRL, Invitrogen), 100 mM non-essential am inoa- 
cids (G IB C O  BRL, Invitrogen) and  2.5% hum an  AB serum  (AB) 
(Bodinco BV, A lkm aar, T h e  Netherlands). 100 ml o f PBM C was 
added  to 100 ml PfAMA1 (30, 6 or 1.2 m g/m l in PBS) in 96 well 
N unclon surface flat plates (Life Technology). Plates w ere incubated 
(six days, +37°C, hum idified 0.5% C O 2) before labelling (10 ml 3H  
thymidine, 0.25 uC i pe r well, 24 hours) an d  harvested onto W allac 
filter m ats using the W allac Beta p late harvester. Incorporated  3H - 
thim idine was determ ined using a W allac Beta Plate counter. 
Stim ulation indices (SI) were calculated relative to control wells to 
w hich no PfAMA1 had been added. PBM C were tested in parallel 
for their ability to be stimulated with T etanus Toxoid (Purified 
T etanus Toxoid  150 L f/m l, R IV M , Bilthoven, T h e  Netherlands) 
and  phytohaem agglutinin 5 m g/m l (PHA-L, Sigma-Aldrich).
In vitro parasite growth inhibition
A ntibodies to be used for parasite inhibition assays were purified 
on  protein  A colum ns (Im m unopure Plus Pierce, St Louis, M O , 
USA) using standard  protocols, exchanged into R P M I 1640 using 
Am icon U ltra-15 concentrators (30 kD a cutoff, M illipore, Ire ­
land), filter-sterilised and  stored a t 2 2 0 ° C  until use. IgG  
concentrations were determ ined using a N anodrop  N D -1000 
spectrophotom eter (N anodrop Technologies, W ilm ington, DE, 
USA).
P. falciparum strain FC R 3 was cultured in vitro using standard  
Pfalciparum culture techniques in an  a tm osphere o f 5% C O 2, 5%
O 2 and  90%  N 2. FC R 3 AMA1 (accession no. M 34553) differs by 
one am ino acid in the pro-sequence from  FV O  AMA1 (accession 
no. AJ277646).
T h e  effect o f purified IgG  antibodies on  parasite  invasion was 
evaluated with two IgG  concentrations (5 and  10 m g /m L , 
respectively) in triplicate using 96 well flat-bottom ed plates 
(Greiner) with synchronized cultures o f P. falciparum schizonts at 
a  starting parasitem ia o f 0 .2 -0 .4% , a  haem atocrit o f  2.0% and  a 
final volum e of 100 mL containing 10% control non-im m une 
h u m an  serum , 20 mg m L 1 gentam icin in  R P M I 1640. After 40 
to 42 hours, cultures were resuspended, and  50 mL was transferred 
into 200 mL ice-cold PBS. T h e  cultures were then  centrifuged, the 
supernatan t rem oved and  the plates w ere frozen. Inhib ition  o f 
parasite  grow th was estim ated using the p L D H  assay as previously 
described (14). Parasite grow th inhibition, reported  as a  percen t­
age, was calculated as follows: 100 — ((Odexperimentai — Odbackground)/ 
(O d;ontrol—0 d background)x100). IgG  purified from  plasm a before 
im m unisation was used as a  control, and  culture m edium  was used 
to m easure the background O d.
Statistical methods
Safety analyses were based on intention  to trea t da ta  selection 
(n = 56). For im m unology assays, pe r protocol analyses were used 
(n = 47). Between group differences were calculated by one-way 
A N O V A , using post-hoc Bonferroni w hen p < 0 .0 5 . Differences 
betw een high an d  low dose groups were com pared  w ith M an n ­
W hitney U  test.
Results
Study population
Participants were recruited a t the R ad b o u d  University N ijm e­
gen M edical C entre  from  Septem ber to O ctober 2005. O f  92 adult 
males screened in and  having provided inform ed consent, 56 were 
eligible and  enrolled (fig. 1). M ain  reasons for exclusion were 
abnorm al laboratory  param eters o r unable to be closely m onitored  
for social, geographic or psychological reasons. T ab le  1 shows the 
dem ographics o f volunteers pe r random ised group. T h e  m ean  age 
was 23 years old (range 18-42 years) an d  all bu t one were 
Caucasian.
Safety and reactogenicity
No serious adverse events occurred th a t were definitely, 
probably, or possibly related to im m unisation. No clinically 
relevant changes in vital signs o r laboratory  values were reported  
th roughout the study. Forty-seven volunteers (84%) received all 
three  im m unisations; nine were excluded for one or m ore 
im m unisations (fig. 1). Tw o o f these were excluded for reasons 
unrela ted  to the trial procedures. O ne  (AlhydrogelTM 10 mg 
group) developed a generalised rash  assessed as unrela ted  to the 
vaccine betw een the first and  second im m unisations and  one 
(M ontanide 10 mg group) received a  concom itant hepatitis B 
im m unisation. Seven volunteers were excluded because they 
developed grade 3 erythem a (diam eter > 5 0  mm) after the second 
im m unisation; one in the M ontanide 10 mg group, the o ther six in 
the AS02 groups (two in the 10 mg group, four in the 50 mg 
group).
V olunteers in all groups presented  w ith local injection site 
reactions, the m ost p redom inan t being transient m ild to m oderate 
pain  (80-100% , table 2). E rythem a was com m only observed (10 of 
17 volunteers) in the AS02 adjuvanted  groups, occurring  after the 
second an d  th ird  im m unisation. In  the M ontanide group 4 o f 18 
volunteers developed erythem a. Seven volunteers reported  grade 3 
ery them a and  were w ithdraw n from  further im m unisation after 
dose 2. T h e  skin in grade 3 (diam eter > 5 0  mm) erythem a was not 
painful and  did no t lim it daily activities. Episodes o f erythem a 
generally lasted 2 -3  days.
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N= 10 
Alum 10(ig
Withdrawn: 
N = 1 
rash
92 assessed for eligibility 
-------- ï =
56 randomised
X
N = 10 
Alum 50jig
I
X
36 not meeting inclusion 
criteria
N = 10 
Mon 10ng
Withdrawn: 
N = 0
X
N = 9 
Mon 50ng
Withdrawn: 
N = 2 
erythema 
other vac.
Withdrawn: 
N = 0
I
Withdrawn: 
N = 2 
erythema
56 completing follow-up (ITT analysis)
47 completing all immunisations (PP analysis)
N = 9 N = 8
AS02 10|ig AS02 50>ig
Withdrawn: 
N = 4 
erythema
Completed Completed Completed Completed Completed Completed
N = 9 N= 10 N = 8 N = 9 N = 7 N = 4
Figure 1. Study flow  chart showing num ber of volunteers randomised, w ithdrawn and com pleting follow-up. Coding for adjuvant as 
follows: Alum = Alhydrogel™, Mon = Montanide. Reasons for withdrawal are given: ''rash''= allergic rash unrelated to study procedure, 
''erythema''= grade 3 injection site erythema leading to withdrawal, ''other vac." = concomitant Hepatitis B vaccination leading to exclusion. 
doi:10.1371/journal.pone.0003960.g001
Induration  a t the site o f injection occurred  in three  volunteers in 
the course o f  the study (table 2). O n e  volunteer, in the M ontanide 
10 mg group, developed m oderate induration  15 days after the first 
im m unisation, lasting for five days. T h e  second and  th ird  
im m unisations in this volunteer were well tolerated; induration  
did no t re-appear. A nother volunteer developed induration  
starting nine days after the first im m unisation in the left arm  with 
50 mg PfA M Al in M ontanide, lasting 25 days. T h e  second 
im m unisation was well tolerated, b u t the left arm  induration  re­
appeared  one day after the th ird  im m unisation, accom panied by 
pain  an d  induration  a t the previous im m unisation site in the 
contralateral (right) arm . Four weeks later, the induration  becam e 
soft and  fluctuated, indicating abcess form ation. A total o f 63 ml o f 
opaque, b row n fluid was aspirated  by  two subsequent punctures,
Table 1. Demographic data, race and age of volunteers per 
dose and adjuvant group.
Adjuvant Aluminum Montanide AS02 All
P/AMA1 dose 10 mg 50 mg 10 mg 50 mg 10 mg
a05
N 10 10 10 9 9 8 56
Race Caucasian 10 10 10 9 8 8 55
Oriental - . . .  1 -
Age
(years)
Mean 22.4 22.6 22.5 22.6 24.1 24.4 23.0
STD 3.1 2.0 4.5 3.8 7.3 6.1 4.6
Minimum 18 19 18 19 19 18 18
Maximum 29 26 33 31 42 36 42
doi:10.1371/journal.pone.0003960.t001
after w hich the abscess and  induration  resolved spontaneously and  
disappeared com pletely a t 81 days post th ird  im m unisation. T he 
th ird  volunteer, also in the 50 mg PfA M A l adjuvanted  with 
M ontanide group, developed m oderate induration  nine days after 
the second im m unisation w hich lasted approxim ately one week. 
Six days after the th ird  im m unisation he developed induration  at 
his left arm  (the site o f  the first and  last im m unisation) which 
eventually started fluctuating. A total o f  130 ml brow n, opaque 
fluid was collected by m eans o f two punctures. T hereafter, 
spontaneous percutaneous drainage occurred  an d  the lesion 
resolved 57 days after the th ird  im m unisation. Both volunteers 
d id no t have any systemic symptoms such as fever during  this time 
period. Abcesses were only mildly painful, bu t lim ited volunteers 
daily activities because o f their size.
T h e  aspirated  fluids from  bo th  volunteers were ab u n d an t in red 
blood cells and  lymphocytes with low C reatinine K inase (CK) 
levels. R epeated  cultures did no t reveal any bacterial con tam ina­
tion. Serum  C K  levels were norm al. C irculating levels o f C- 
reactive p rotein  rem ained  below detection levels (indicating that 
the reaction was a local response). U ltrasound exam ination 
suggested an  intram uscular an d  subcutaneous localisation o f the 
fluid-filled cavity.
Systemic reactions were infrequent in the A lhydrogelTM and  
M ontanide groups and  occurred  m ainly in the AS02 groups. T he 
systemic adverse events occurred  w ithin 24 hours o f im m unisation 
and  usually resolved w ithin two days. T h e  m ost prevalent systemic 
adverse events w ere headache (77.8-87.5% ) and  malaise (66.7­
87.5%) in the AS02 groups. Four o f those volunteers reported  
grade 3 headache or m alaise. M ost o f  the systemic adverse events 
occurred  after dose 2. T h ere  was no effect o f  antigen dose on 
reactogenicity. No changes in blood pressure w ere no ted  in any of 
these volunteers.
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Table 2. Number of volunteers reporting vaccine related adverse events per dose and adjuvant group.
Adjuvant Alum Montanide AS02 Total
PfAMA1 dose 10 mg 50  mg 10 mg 50  mg 10 mg 50 mg
N 9 8
Total 8 (80.0%) 10 (100%) 9 (90.0%) 9 (100%) 9 (100%) 8 (100%) S3 (94.6%)
LOCAL
Pain 8 (80.0%) 10 (100%) 8 (80.0%) 9 (100%) 9 (100%) 8 (100%) S2 (92.9%)
Erythema - - 2 (20.0%) 2 (22.2%) 4 (44.4%) 6 (7S.0%) 14 (2S%)
Swelling - - 1 (10.0%) - 3 (33.3%) 1 (12.S%) S (8.9%)
Induration - - 1 (10.0%) 2 (22.2%) - - 3 (S.4%)
Sterile abscess - - - 2 (22.2%) - - 2 (3.6%)
SYSTEMIC
Headache 1 (10.0%) - 2 (20.0%) - 6 (66.7%) 7 (87.S%) 16 (28.6%)
Malaise - - - 1 (11.1%) 6 (66.7%) 7 (87.S%) 14 (2S.0%)
Fever - - - - S (55.6%) S (62.S%) 10 (17.9%)
Myalgia - - - - 4 (44.4%) 2 (2S.0%) 6 (10.7%)
Nausea 1 (10.0%) - - - 1 (11.1%) 2 (2S.0%) 4 (7.1%)
Fatigue - - - - - 2 (2S.0%) 2 (3.6%)
Arthralgia - - - - 1 (11.1%) - 1 (1.8%)
Abdominal pain - - - - 1 (11.1%) - 1 (1.8%)
doi:10.1371/journal.pone.0003960.t002
Humoral immune response
Peak antibody titers were observed one m onth  after the final 
im m unisation. 100% o f volunteers in the 10 and  50 mg AS02 and 
50 mg M ontanide groups showed a  greater th an  four-fold increase 
in antibody titer over pre-im m unisation com pared to 60% in the 
10 mg AlhydrogelTM, 80% in the 50 mg A lhydrogel™  and  90%  in 
the 10 mg M ontanide groups (fig. 2). All vaccinees had  reached IgG  
titers com parable to or higher than  semi im m une sera. T w o and 
four m onths post final im m unisation bo th  AS02 groups an d  the 
M ontanide 50 mg group showed the highest IgG  titers b u t given the 
small sample sizes there was no pow er to detect statistical differences 
betw een groups. Antibody titers decreased further one year post 
im m unisation, with the steepest decline being in the M ontanide 
groups, to a  level com parable w ith the reference AlhydrogelTM 
groups. O ne year post vaccination, titers in the 10 mg AS02 group 
were significantly higher as com pared to the reference group (post 
hoc Bonferroni w hen com pared with low dose A lhydrogel™  
reference group p < 0 .0 1 , 95% CI 0.25 to1.5). Vaccinees receiving 
50 mg PfAMA1 generally showed a  trend  towards higher antibody 
titers than  the corresponding 10 mg group, except for the AS02 
groups w here antibody titers were no t antigen dose-dependent.
Sera from  vaccinees could be shown to recognise the native 
PfAMA1 by im m unofluorescence in a  dose dependent m anner. 
E ight o f  fifteen samples were positive in IFA, am ongst w hich were 
four samples w ith the highest antibody titers. T h e  staining patte rn  
found in  positive samples localised to the same structures as 4G2 
ra t m onoclonal antibody (fig. 3).
Cellular immune response
In  all groups, induction of IFN y and  IL-5 cytokines could be 
dem onstra ted  (fig. 4). T he m agnitude o f cytokine production  was 
no t dose dependent or dependent on the num ber o f im m unisa­
tions. R ather, IFN y p roduction  in  m any samples decreased after 
the th ird  im m unisation. For bo th  cytokines, PfAMA1 induction 
was com parable o r h igher th an  th a t following stim ulation with
5 mg T etanus Toxoid  (data no t shown). Cytokine production  in 
the different groups did no t differ significantly from  each o ther (for 
IN Fy p  = 0.18, for IL-5 p  = 0.14). R a tio ’s o f IFN y /  IL-5 
production  were also no t significantly different betw een adjuvant 
groups (data no t shown), b u t showed a  trend  tow ards h igher ratio 
in the M ontanide and  AS02 groups (Day 84 m ean  ratio 
Alhydrogel: 1.16 (95% CI: 0.08 to 2.23), M ontanide: 2.82 (95% 
CI: 1.44 to 4.21), AS02: 2.66 (95% CI: 0.57 to 4.76)).
All groups showed Peripheral Blood M ononuclear Cell 
proliferation upon  stim ulation with PfAMA1 (fig. 5). Stim ulation 
indices betw een PB M C ’s stim ulated w ith 30, 6 or 1.2 m g/m l 
PfAMA1 were similar. All groups o f volunteers showed significant 
increase in proliferation upon stim ulation w ith PfAMA1 after the 
second im m unisation. After the th ird  im m unisation none o f the 
groups showed a further increase in stim ulation index, ra th e r the 
10 mg M ontanide group showed a  significant decrease after the 
th ird  im m unisation (p = 0.03). T h ere  were no significant differ­
ences in stim ulation index betw een the different adjuvant o r dose 
groups.
In vitro parasite growth inhibition
T o estim ate functionality o f the induced antibodies, an  in vitro 
G IA  was perform ed. Results are shown as percentage inhibition 
com pared to pre-vaccination sera from  the same individual (fig. 6). 
A t a  concentration  o f 10 m g /m l, the m edian  grow th inhibition in 
the M ontan ide 50 mg and  AS02 groups was abou t 30%  and  50% 
respectively. In  the AlhydrogelTM and  M ontanide 10 mg groups 
m edian inhibition was lower, ranging from  4 to 17%. O nly 
differences betw een A lhydrogel™  and  AS02 groups were 
significant (p = 0.002).
Discussion
This trial dem onstrates th a t reactogenicity o f PfAMA1- 
FV O [25-545] varies, depending on the adjuvant. Im m unogenicity
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Figure 2. Mean log anti-AMA-1 titers w ith  standard error of the mean for low and high dose per adjuvant group. Anti-AMA-1 titers 
were determined by ELISA for the six different groups, immunized with Alhydrogel1M, Montanide and AS02 adjuvanted PfAMA1 vaccine. Dashed lines 
represent high dose of PfAMAI (50 mg), continuous lines represent low dose groups (10 mg). Measurements were performed at baseline, 28 days after 
the first, second and third immunisation (day 28, 56 and 84 respectively) and day 140 and 365. 
doi:10.1371/journal.pone.0003960.g002
a t bo th  high and  low doses and  in all ad juvant form ulations is PfAM A1-FVO[25-545] m ixed with the adjuvants Alhydrogel™, 
good, although the type and  m agnitude o f im m une response M ontanide and  AS02 tended  to be locally reactogenic, m ainly 
varied am ong different adjuvant groups. causing short lasting injection site pain  w hen adm inistered to
Figure 3. Representative immunofluorescent microscopy picture, showing recognition of native antigen on merozoites by induced 
anti-AMA1 antibodies. Immunofluorescence picture of merozoites incubated with 40x diluted anti-AMA1 plasma from an immunized volunteer 
one month after final immunisation stained with Rabbit anti-human immunoglobulin FITC (A) and DAPI (B). Photo was taken at magnification 400x. 
Incubation with monoclonal antibody 4G2, a pan-specific anti-AMA1 antibody, confirmed the surface staining pattern (not shown). 
doi:10.1371/journal.pone.0003960.g003
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Figure 4. ELISPOT assay for IFNy (A) and IL-5 (B) after stimulation w ith  6 mg P A M A 1. Peripheral Blood Mononuclear Cells from immunised 
volunteers 28 days after the second immunisation and 28 days after the third immunisation (day 56 and 84 respectively) were stimulated with 6 mg of 
PfAMA1 vaccine. Production of IFNy and IL-5 was measured by counting spots in ELISPOT plates. Box plots and whiskers show the range and the 25th, 
50th and 75th percentile of spots per 2x105 cells. Circles represent outliers. 
doi:10.1371/journal.pone.0003960.g004
healthy adult volunteers. M ost post imm unisations adverse events 
were m ild-to-m oderate in intensity and  have been seen previously 
with o ther vaccines[35-40]. Because this was the first time Pichia 
Pastoris p roduced  FV O  PfAM AI antigen was being given to 
hum ans, the occurrence o f a  grade 3 adverse event was a  stopping 
criterium , w hich led to w ithdraw al o f seven subjects post dose 2 for 
grade 3 (> 5 0  mm) erythem a. However, the erythem a observed 
resolved spontaneously w ithin three days o f onset w ithout any 
sequelae. T he erythem a is no t considered a  h indrance for further 
vaccination with the AS02 adjuvant. In  term s o f systemic adverse 
events, m ost were related to the AS02 adjuvant and  transient 
resolving w ithin two days with no sequelae. T h e  pa tte rn  o f transient, 
prim arily m ild to m oderate systemic adverse events has been 
reported  with ano ther AMA-1 antigen adjuvanted w ith AS02 [41].
T h ree  im m unisations with 50 mg PfAM AI adjuvanted  by 
M ontanide induced a  sterile abscess in two o f ten  volunteers. 
Progression of induration  to a  sterile abscess has been  previously
reported  before after im m unisation with M ontanide [42-44]. In 
all reports the developm ent o f an  abscess followed intram uscular 
im m unisation and  was accom panied  by enhanced  im m unogenic- 
ity. T h e  increased reactogenicity o f M ontanide-adjuvanted  
vaccines has been  a ttribu ted  to a  com bination o f antigen dose 
and  the form ation o f a  vaccine depot th a t m ay persist locally and  
th a t is inheren t to water-in-oil emulsions [45]. Similarly, 
induration  a t the previous im m unisation site has been  a ttribu ted  
to persistent antigen in previous trials [46]. A less condensed 
vaccination regim en and  avoidance o f the same injection sites m ay 
be m easures to avoid induration.
T o  date, there are four other reports on clinical phase Ia trials o f a 
PA M A 1 vaccine. These trials employed different PA M A 1 constructs 
and utilized different adjuvants. T he constructs were o f P. pastoris or E. 
coli origin or used a virally vectored delivery system [47-50].
T h e  P. pastoris-produced PfAMA1 com prised recom binant 
proteins based on sequences from  the ectodom ains o f F V O  and
Figure 5. Stimulation indices in response to 6 mg/ml PAM A1 presented as box plots and whiskers. Peripheral Blood Mononuclear Cells 
from immunised volunteers 28 days after the second immunisation and 28 days after the third immunisation (Day 56 and 84 respectively) were 
stimulated with 6 mg of PfAMA1 vaccine. Cell proliferation was measured by adding 3H thymidine and calculated relative to control wells. Box plots 
and whiskers show the range and the 25th, 50th and 75th percentile. Circles represent outliers. Measurements were performed at baseline, 28 days 
after the second immunisation and 28 days after the third immunisation (day 56 and 84 respectively). 
doi:10.1371/journal.pone.0003960.g005
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Figure 6. Percentage of growth inhibition of FVO-strain P. falciparum  parasites after addition of 5 or 10 mg/ml IgG. Serum samples 
from volunteers immunised with PfAMA1 were obtained four weeks after the final immunisation by per protocol analysis and included in a merozoite 
growth inhibition assay. Growth inhibition is expressed as a percentage to control.Boxes show 25th, 50th and 75th percentile growth inhibition, 
whiskers show the range, circles are outliers. 
doi:10.1371/journal.pone.0003960.g006
3D7 strain AMA1 adjuvanted  with AlhydrogeirM have been tested 
bo th  in a  phase Ia  and  Ib trial. As with previous studies in which 
m alarial antigens have been adjuvanted  w ith Alhydrogei™, this 
candidate vaccine showed an  acceptable reactogenicity profile bu t 
a  lim ited im m une response. T h e  M alkin e t al. phase Ia  trial shows 
a  G IA  response in only 4 o f 22 subjects despite high 
seroconversion rates [51], similar to the data  obtained here with 
Alhydrogei1™. Interestingly, in our study, the P. pastoris PfAMA1 
com bined with Alhydrogei™' was m uch less reactogenic and  did not 
produce any ery them a or induration , even though  the doses were 
com parable. T h e  lower A lhydrogel dose (500 mg per im m unisa­
tion) used in this trial, as com pared  to M alkin et al. (800 mg) m ay 
also play a  role in its decreased reactogenicity.
T here  are two trials utilizing the E. coli-produced 3D7 strain 
AM A1, one reconstituted in M ontanide and  a  second form ulated in 
AS02. T h e  A M A 1-M ontanide com bination was considered safe bu t 
the trial was com prom ised by ap p aren t loss o f potency [52]. T he 
AM A1-AS02 com bination [53] showed com parable local and 
systemic reactogenicity. A lthough Polhem us et al. w ere able to show 
recognition o f the native antigen by IFA, growth inhibition results 
were approxim ately two fold lower than  those found in this study.
Lastly, PfAMA1 has also been evaluated in a  m ulti-antigen 
m alaria  vaccine delivered in an  a ttenuated  vaccinia virus.
A lthough w eak protective effects were found, im m unogenicity in 
th a t trial was poor [54].
After one year follow-up, we found antibody levels still to be 
significantly h igher than  baseline for all groups. This is in sharp 
contrast to the results o f M alkin et al. [55] who reported  detectable 
antibodies in only 50-90%  of volunteers by day 364, even though 
they had  been  boosted m uch later (on D ay 180). T his suggests that 
a  m ore condensed im m unisation regim e m ay affect the persistence 
o f antibodies.
In  this trial we have shown th a t the com bination  o f clinical 
grade PfAMA1 F V O  [25-545] P. pastoris expressed m aterial with 
either M ontanide or AS02 is significantly m ore im m unogenic than  
previous PfAMA1 form ulations, being capable o f inducing high 
levels o f  antibodies for bo th  dosages in bo th  adjuvant groups. A 
positive trend  betw een antigen dose, antibody response an d  in vitro 
parasite  growth inhibition could be detected, although the effect o f 
antigen dose on  im m unogenicity was negligible com pared  to the 
effect o f varying the adjuvant. T h e  wide variety o f im m une 
responses found in different adjuvant form ulations stresses the 
im portance o f adjuvants as a  critical com ponent in m alaria  
vaccine developm ent.
T h e  functionality o f vaccine induced antibodies was assessed by 
grow th inhibition assay. A lthough this assay has no t been validated
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as a  correlate o f protection, this trial dem onstrates th a t the 
standardised assay is able to dem onstrate recognition o f the native 
p rotein  and  thus functionality in  vitro.
D ifferent adjuvants are known to p ro m p t im m une responses 
towards Th1 or T h2 . It has been  previously reported  th a t AS02 
induces an  im m une response skewed tow ards Th1 [56], with 
p roduction  o f prim arily  IFN y. In  contrast AlhydrogelrM is know n to 
be T h2  inducer [57]. In  this study, ra tio ’s o f cytokine production  
a t day 84 showed relatively m ore IFN y over IL-5 p roduction  in 
the M ontanide and  AS02 groups suggesting a  pro-T h1 response, 
although statistically non-significant. Interestingly, the additional 
th ird  im m unisation generally did no t lead  to a  further increase in 
IFN y or IL-5 production  or in lym phocyte proliferation. R ather, 
m any volunteers showed a  reduction  in the response after the th ird  
im m unisation. T his difference could no t be explained by inter-test 
variability. It rem ains to be investigated if it indicates a  shift in the 
relative balance betw een im m ediate effector cells and  long-lived 
m em ory cells.
A lthough this phase I trial is lim ited w ith respect to the size and  
generalizibility to the target population , it m et its objectives to 
outline a  generalizable safety profile. Specifically the direct 
com parison of the safety profile o f different adjuvants is valuable 
for future developm ent o f AMA1 an d  o ther m alaria  vaccines. 
Furtherm ore, the m alaria  vaccine candidate AMA1 provides the 
possibility o f assessing functionality o f the im m une response by  a 
parasite growth inhibition assay. How ever, it m ust be no ted  that 
the grow th inhibition assay is no t validated as a  correlate o f 
protection, an d  is as such a  lim ited p red ictor for efficacy.
W ith  this study we have shown th a t the PfAMA1 vaccine 
com bined w ith different adjuvants, Alhydrogel™, M ontanide and  
AS02 provided distinct reactogenicity profiles. All vaccine 
form ulation were im m unogenic a t bo th  dosages. G row th inhibi­
tion results indicate th a t induction o f functional im m une responses 
is p robably  dependent on adjuvant, underscoring the need for 
strong im m unopotentiators for m alaria  vaccines. A ltogether, these 
results are prom ising for a  future developm ent o f a  PfAMA1 
m alaria  vaccine.
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